Van Cutsem E, et al. - In the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial, researchers tested selective combination targeted therapy for BRAF V600E–mutant metastatic colorectal cancer (mCRC), focusing on safety and preliminary efficacy. Recruitment of 30 cases that showed treatment failure with one or two prior regimens, to a safety lead-in of encorafenib 300 mg daily, binimetinib 45 mg twice daily, plus standard weekly cetuximab, was done prior to the beginning of the randomized portion of the BEACON Colorectal Cancer trial. According to findings, the encorafenib, binimetinib, and cetuximab regimen demonstrated manageable safety and tolerability in the safety lead-in, which was also found to be acceptable for initiation of the randomized portion of the study. This treatment regimen offered promising efficacy as compared with available therapies. Moreover, this regimen could be approved as a new standard of care for previously treated BRAF V600E–mutant mCRC provided it gets validation in the randomized portion of the trial.